Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | F10 | P00742 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 3/20 | 0.46 |
| ▸ | PLAT | P00750 | 3/20 | 0.46 |
| ▸ | PLG | P00747 | 2/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TCF4 | P15884 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15525729 | 0.83 | TBXA2R (0.58) | PLAUPLAT | |
| SCHEMBL9436735 | 0.82 | PKM (0.56) | CA12CA1CA2CA9F10 | |
| SCHEMBL16375994 | 0.82 | P2RX4 (0.48) | P2RX4ACLYCYP2C9PTGES2 | |
| SCHEMBL19039475 | 0.82 | WDR5 (0.46) | CA2CA9F10PLAUP2RX4 | |
| SCHEMBL18574241 | 0.80 | P2RX4 (0.41) | F10PLAUP2RX4CYP1A2POLB | |
| SCHEMBL19039474 | 0.79 | AR (0.46) | CA12CA1CA2CA9F10 | |
| SCHEMBL19625141 | 0.79 | PLG (0.48) | F10PLAUPLATPLGACLY | |
| SCHEMBL16376159 | 0.78 | TBXA2R (0.52) | F10PLAUKMT2APOLB | |
| SCHEMBL21962198 | 0.77 | PKM (0.74) | CA12CA1CA2CA9PKM | |
| SCHEMBL15525704 | 0.76 | CA2 (0.56) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838519-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | UNIV COLLEGE DUBLIN NAT UNIV OF IRELAND DUBLIN (IE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2838519-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | UNIV COLLEGE DUBLIN NAT UNIV OF IRELAND DUBLIN (IE) | 2017-11-22 | — | — | EP | disclosed |
| US-20170298020-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | ATXA THERAPEUTICS LIMITED (IE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298020-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | ATXA THERAPEUTICS LIMITED (IE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298020-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | ATXA THERAPEUTICS LIMITED (IE) | 2017-10-19 | — | — | US | disclosed |
| US-9738599-B2 | Thromboxane receptor antagonists | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-08-22 | — | — | US | disclosed |
| US-9738599-B2 | Thromboxane receptor antagonists | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-08-22 | — | — | US | disclosed |
| US-9738599-B2 | Thromboxane receptor antagonists | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-08-22 | — | — | US | disclosed |
| US-9718781-B2 | Methods and compounds for treating proliferative disorders and viral infections | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-08-01 | — | — | US | disclosed |
| US-9718781-B2 | Methods and compounds for treating proliferative disorders and viral infections | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-08-01 | — | — | US | disclosed |
| US-20160102051-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | ATXA THERAPEUTICS LIMITED (IE) | 2016-04-14 | — | — | US | disclosed |
| US-20160016900-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LIMITED (IE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016900-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LIMITED (IE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016900-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LIMITED (IE) | 2016-01-21 | — | — | US | disclosed |
| EP-2838520-A2 | THROMBOXANE RECEPTOR ANTAGONISTS | University College Dublin National University Of Ireland, Dublin (IE) | 2015-02-25 | — | — | EP | disclosed |
| EP-2838519-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | University College Dublin National University Of Ireland, Dublin (IE) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013156871-A9 | THROMBOXANE RECEPTOR ANTAGONISTS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-01-08 | — | — | WO | disclosed |
| WO-2013156871-A9 | THROMBOXANE RECEPTOR ANTAGONISTS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-01-08 | — | — | WO | disclosed |
| WO-2013156871-A2 | THROMBOXANE RECEPTOR ANTAGONISTS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013156861-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102051-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | TBXA2R, PTGFR, TBXAS1 | CA12 4381/4885CA1 4728/4885CA2 3111/4885 |
| US-20170298020-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | TBXA2R, PTGFR, TBXAS1 | CA12 4381/4885CA1 4728/4885CA2 3111/4885 |
| US-20160016900-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | TBXA2R, TBXAS1, PTGIR | CA12 4434/4885CA1 4340/4885CA2 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.